From: Metabolic phenotype in Darier disease: a cross-sectional clinical study
Baseline characteristics | DD patients | Control patients | p-value |
---|---|---|---|
n | 25 | 25 | |
Age (years) | 52 ± 13 (27–78) | 51 ± 13 (27–76) | 0.80# |
Male sex | 10 (40) | 10 (40) | 1.000† |
BMI (kg/m2) | 28.2 ± 5.3 (18.9–42.3) | 27.0 ± 5.0 (19.8–38.7) | 0.45# |
Weight (kg) | 81.4 ± 17.8 (54–119) | 78.8 ± 18.2 (49.3–117) | 0.73# |
Height (cm) | 169.6 ± 9.9 (152–193) | 170.3 ± 11.5 (48.5–193) | 0.83# |
Current smoker | 5 (20) | 2 (8) | 0.417† |
DM family history | 13 (52) | 11 (44) | 0.778† |
Acitretin treatment | 14 (56) | 0 (0) | < 0.001†* |
Hypertension treatment | 3 (12) | 4 (16) | 1.000† |
Dyslipidemia treatment | 3 (12) | 2 (8) | 1.000† |
Glucose metabolism | |||
Fasting plasma glucose (mmol/L) | 5.3 ± 0.4 | 5.6 ± 0.5 | 0.07# |
2-h plasma glucose (mmol/L) | 5.6 ± 1.7 | 5.7 ± 1.3 | 0.68# |
HbA1c (mmol/mol) | 36±4 | 36 ± 4 | 0.36# |
Beta cell function | |||
Proinsulin/insulin (ratio) | 0.85 ± 0.32 | 0.80 ± 0.49 | 0.19# |
C-peptide (nmol/L) | 0.8 ± 0.2 | 0.7 ± 0.2 | 0.24# |
HOMA2-%S HOMA2-%B | 79.6 ± 32.7 122.7 ± 27.1 | 94.9 ± 52.4 103.5 ± 22.1 | 0.53# 0.01#* |